BR112014016805A8 - compostos terapeuticamente ativos e seus métodos de uso - Google Patents

compostos terapeuticamente ativos e seus métodos de uso

Info

Publication number
BR112014016805A8
BR112014016805A8 BR112014016805A BR112014016805A BR112014016805A8 BR 112014016805 A8 BR112014016805 A8 BR 112014016805A8 BR 112014016805 A BR112014016805 A BR 112014016805A BR 112014016805 A BR112014016805 A BR 112014016805A BR 112014016805 A8 BR112014016805 A8 BR 112014016805A8
Authority
BR
Brazil
Prior art keywords
methods
therapeutically active
active compounds
administering
subject
Prior art date
Application number
BR112014016805A
Other languages
English (en)
Other versions
BR112014016805B1 (pt
BR112014016805A2 (pt
Inventor
Delabarre Byron
G Salituro Francesco
Cianchetta Giovanni
Popovici-Muller Janeta
O Saunders Jeffrey
Travins Jeremy
Zhang Li
Yan Shunqi
Guo Tao
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48744984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014016805(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of BR112014016805A2 publication Critical patent/BR112014016805A2/pt
Publication of BR112014016805A8 publication Critical patent/BR112014016805A8/pt
Publication of BR112014016805B1 publication Critical patent/BR112014016805B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo compostos terapeuticamente ativos e seus métodos de uso proporcionam-se os compostos úteis para o tratamento de câncer e métodos para tratar o câncer compreendendo a administração a um sujeito que dele necessite um composto aqui descrito.
BR112014016805-9A 2012-01-06 2013-01-05 Compostos derivados de triazina, composição farmacêutica compreendendo os referidos compostos e seu uso para preparar um medicamento BR112014016805B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584214P 2012-01-06 2012-01-06
US61/584,214 2012-01-06
PCT/CN2013/000009 WO2013102431A1 (en) 2012-01-06 2013-01-05 Therapeutically active compounds and their methods of use

Publications (3)

Publication Number Publication Date
BR112014016805A2 BR112014016805A2 (pt) 2017-06-13
BR112014016805A8 true BR112014016805A8 (pt) 2017-07-04
BR112014016805B1 BR112014016805B1 (pt) 2019-07-30

Family

ID=48744984

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016805-9A BR112014016805B1 (pt) 2012-01-06 2013-01-05 Compostos derivados de triazina, composição farmacêutica compreendendo os referidos compostos e seu uso para preparar um medicamento

Country Status (39)

Country Link
US (7) US9732062B2 (pt)
EP (3) EP3406608B8 (pt)
JP (2) JP6411895B2 (pt)
KR (1) KR101893112B1 (pt)
CN (6) CN115536635A (pt)
AR (1) AR090411A1 (pt)
AU (2) AU2013207289B2 (pt)
BR (1) BR112014016805B1 (pt)
CA (1) CA2860623A1 (pt)
CL (1) CL2014001793A1 (pt)
CO (1) CO7030962A2 (pt)
CR (1) CR20140377A (pt)
CY (1) CY1120506T1 (pt)
DK (1) DK2800743T3 (pt)
EA (1) EA030187B1 (pt)
EC (1) ECSP14012726A (pt)
ES (2) ES2901430T3 (pt)
HK (1) HK1203942A1 (pt)
HR (1) HRP20180844T1 (pt)
HU (1) HUE038403T2 (pt)
IL (1) IL233503B (pt)
LT (1) LT2800743T (pt)
MX (1) MX358940B (pt)
MY (1) MY185206A (pt)
NI (1) NI201400073A (pt)
NO (1) NO2897546T3 (pt)
NZ (2) NZ722582A (pt)
PE (1) PE20142098A1 (pt)
PH (1) PH12014501561B1 (pt)
PL (1) PL2800743T3 (pt)
PT (1) PT2800743T (pt)
RS (1) RS57401B1 (pt)
SG (2) SG11201403878QA (pt)
SI (1) SI2800743T1 (pt)
TR (1) TR201809228T4 (pt)
TW (1) TWI653228B (pt)
UA (1) UA117451C2 (pt)
WO (1) WO2013102431A1 (pt)
ZA (1) ZA201405163B (pt)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010105243A1 (en) 2009-03-13 2010-09-16 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US8785450B2 (en) 2009-06-29 2014-07-22 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
PL3406251T3 (pl) 2011-05-03 2024-04-29 Agios Pharmaceuticals, Inc. Aktywatory kinazy pirogronianowej do stosowania w terapii
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN107982266B (zh) 2012-01-06 2021-07-30 H.隆德贝克有限公司 氨基甲酸酯化合物及其制备和使用方法
SI2800743T1 (en) 2012-01-06 2018-08-31 Agios Pharmaceuticals, Inc. Therapeutically active compounds and methods for their use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105473560B (zh) * 2013-07-11 2020-01-17 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
EP3019480B1 (en) * 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
MY185687A (en) * 2013-07-11 2021-05-30 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
KR102316886B1 (ko) * 2013-08-02 2021-10-19 아지오스 파마슈티컬스 아이엔씨. 치료학적 활성 화합물 및 이의 사용방법
EA030428B1 (ru) * 2013-08-02 2018-08-31 Аджиос Фармасьютикалз, Инк. Терапевтически активные соединения и способы их применения
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
KR102400737B1 (ko) * 2014-03-14 2022-05-20 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
JP6524119B2 (ja) * 2014-03-14 2019-06-05 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物の医薬組成物
CN106132946A (zh) * 2014-03-28 2016-11-16 巴斯夫欧洲公司 作为除草剂的二氨基三嗪衍生物
WO2015155129A1 (en) * 2014-04-07 2015-10-15 Basf Se Diaminotriazine compound
EP2930174A1 (en) * 2014-04-07 2015-10-14 Basf Se Diaminotriazine derivatives as herbicides
US10005734B2 (en) 2014-09-19 2018-06-26 Forma Therapeutics, Inc. Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
MX2017003627A (es) 2014-09-19 2018-01-24 Forma Therapeutics Inc Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
JP6751081B2 (ja) * 2014-09-19 2020-09-02 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
EP4257131A3 (en) * 2014-09-19 2024-01-10 Forma Therapeutics, Inc. Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
KR20170057411A (ko) 2014-09-29 2017-05-24 아지오스 파마슈티컬스 아이엔씨. 치료적 활성 화합물 및 이들의 사용 방법
KR102628370B1 (ko) * 2015-02-04 2024-01-24 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이들의 사용 방법
ES2878041T3 (es) 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
EA038574B1 (ru) * 2015-04-21 2021-09-16 Форма Терапьютикс, Инк. Хинолиноновые производные пиридин-2(1h)-она и фармацевтические композиции на их основе
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016177347A1 (en) * 2015-05-07 2016-11-10 Teligene Ltd Heterocyclic compounds as idh2 inhibitors
CN113413387A (zh) 2015-05-11 2021-09-21 H.隆德贝克有限公司 治疗炎症或神经性疼痛的方法
WO2016201227A1 (en) 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
JP6786086B2 (ja) * 2015-07-30 2020-11-18 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. １，３，５−トリアジン誘導体及びその使用方法
AU2016303614A1 (en) * 2015-08-05 2018-02-15 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
US10905692B2 (en) 2015-10-15 2021-02-02 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
EP4403173A3 (en) 2015-10-15 2024-10-09 Les Laboratoires Servier Combination therapy for treating malignancies
NZ741433A (en) 2015-10-15 2024-07-26 Celgene Corp Combination therapy for treating malignancies
CN107207469B (zh) * 2015-10-21 2018-09-25 纽弗姆制药有限公司 用于治疗血液恶性肿瘤的氘代化合物以及其组合物和方法
CA3007218A1 (en) 2015-12-04 2017-06-08 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
CN105399695B (zh) * 2015-12-11 2019-04-19 浙江大学 三嗪类化合物及其制备方法和用途
CN105384702B (zh) * 2015-12-11 2018-04-10 浙江大学 三取代均三嗪类化合物及其制备方法
CN105503754B (zh) * 2015-12-11 2017-11-17 浙江大学 2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
ES2912909T3 (es) 2016-02-26 2022-05-30 Celgene Corp Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
CN105753801B (zh) * 2016-03-25 2018-06-01 浙江工业大学 一种均三嗪类化合物的制备方法
CN105820133B (zh) * 2016-03-25 2018-06-05 浙江工业大学 多取代均三嗪类化合物及其制备方法和应用
EP3489230B1 (en) * 2016-07-21 2021-12-08 Nanjing Sanhome Pharmaceutical Co., Ltd. Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof
EP3493809B1 (en) * 2016-08-03 2023-08-23 Celgene Corporation Enasidenib for treatment of myelodysplastic syndrome
CA3036053A1 (en) 2016-09-07 2018-03-15 Celgene Corporation Tablet compositions
WO2018053447A1 (en) 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
WO2018133856A1 (zh) * 2017-01-22 2018-07-26 正大天晴药业集团股份有限公司 1，3，5-三嗪衍生物的盐及其晶体、它们的制备方法、药物组合物和用途
EP3618828B1 (en) 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
SG11201913008TA (en) 2017-06-30 2020-01-30 Celgene Corp Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-doxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
CN109265444B (zh) * 2017-07-17 2022-03-11 南京圣和药业股份有限公司 取代的三嗪类idh抑制剂的光学异构体及其应用
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
CN110051673B (zh) * 2018-01-19 2022-03-11 南京圣和药业股份有限公司 一种包含三嗪类idh抑制剂的药物组合物及其用途
CN110054617A (zh) * 2018-01-19 2019-07-26 南京圣和药业股份有限公司 三嗪类化合物、其制备方法及用途
CN110054616B (zh) * 2018-01-19 2021-11-23 南京圣和药业股份有限公司 三嗪类idh抑制剂的制备方法
CN110054615B (zh) * 2018-01-19 2021-06-15 南京圣和药业股份有限公司 三嗪类idh抑制剂甲磺酸盐的晶型
BR112020000863A2 (pt) 2018-05-15 2020-12-08 Lundbeck La Jolla Research Center, Inc. Inibidores de magl
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
WO2019222553A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
CN111662271B (zh) * 2019-03-08 2023-11-14 中国药科大学 具有idh突变体抑制活性的化合物及其制备方法与应用
CN111662275B (zh) * 2019-03-08 2023-08-22 中国药科大学 苯磺酰胺类idh突变体抑制剂、其制备方法和用途
WO2020239759A1 (en) 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
CN114502537A (zh) * 2019-09-29 2022-05-13 贝达药业股份有限公司 突变型idh2抑制剂及其应用
JP2023503842A (ja) 2019-11-14 2023-02-01 セルジーン コーポレーション がんを処置するための小児用製剤
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
CN111592524B (zh) * 2020-05-20 2023-11-17 温州市天聚万迅信息科技有限公司 恩西德尼的制备方法
US20240092802A1 (en) * 2020-10-06 2024-03-21 Kures, Inc. Mu-opioid receptor agonists and uses therefor
KR20230145402A (ko) * 2021-02-12 2023-10-17 르 라보레또레 쎄르비에르 치료적 활성 화합물 및 이의 사용 방법
US11865079B2 (en) 2021-02-12 2024-01-09 Servier Pharmaceuticals Llc Therapeutically active compounds and their methods of use
CN113461660B (zh) * 2021-06-11 2022-08-02 浙江大学 2,4,6-三取代-1,3,5-均三嗪类化合物及制备和应用
CN118786119A (zh) * 2022-03-15 2024-10-15 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
TW202400575A (zh) 2022-03-24 2024-01-01 美商Ａ２Ａ製藥公司 治療癌症的組合物和方法
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途
CN115536637A (zh) * 2022-10-24 2022-12-30 陕西中医药大学 一种均三嗪类衍生物及其合成方法与用途

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3867383A (en) 1971-03-29 1975-02-18 Ciba Geigy Corp Monoanthranilatoanilino-s-triazines
CH606334A5 (pt) 1974-06-21 1978-10-31 Ciba Geigy Ag
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
US5041443A (en) 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
DE69010232T2 (de) 1989-03-03 1994-12-01 Dainippon Pharmaceutical Co 2-(1-Piperazinyl)-4-phenylcycloalkanpyridin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten.
ATE130882T1 (de) 1990-07-12 1995-12-15 Ciba Geigy Ag Verfahren zur photochemischen und thermischen stabilisierung von polyamid-fasermaterialien.
JPH0499768A (ja) 1990-08-17 1992-03-31 Dainippon Pharmaceut Co Ltd ４―（４―フェニルピリジン―２―イル）ピペラジン―１―オキシド誘導体
CA2131004A1 (en) 1992-02-28 1993-09-02 Hideshi Kobayashi S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
WO1997044322A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
EP0945446A4 (en) 1996-11-14 1999-12-08 Nissan Chemical Ind Ltd CYANOETHYLMELAMINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
EP1187825A1 (en) 1999-06-07 2002-03-20 Shire Biochem Inc. Thiophene integrin inhibitors
ATE309207T1 (de) 1999-08-27 2005-11-15 Sugen Inc Phosphat-mimetika sowie behandlungsmethoden unter verwendung von phosphatase-inhibitoren
AU2001267910A1 (en) 2000-07-03 2002-01-14 Kansai Paint Co. Ltd. Gas-barrier film
KR20030024799A (ko) 2000-07-20 2003-03-26 뉴로젠 코포레이션 캡사이신 수용체 리간드
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
JP4344241B2 (ja) 2001-08-17 2009-10-14 チバ ホールディング インコーポレーテッド トリアジン誘導体、およびサンスクリーンとしてのその使用
JP4753336B2 (ja) 2001-09-04 2011-08-24 日本化薬株式会社 新規アリル化合物及びその製法
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
US6878196B2 (en) 2002-01-15 2005-04-12 Fuji Photo Film Co., Ltd. Ink, ink jet recording method and azo compound
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
JP2004107220A (ja) 2002-09-13 2004-04-08 Mitsubishi Pharma Corp ＴＮＦ−α産生抑制剤
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
EP1575580A4 (en) 2002-12-02 2009-06-10 Arqule Inc METHODS OF TREATING CANCERS
ES2373947T3 (es) 2002-12-16 2012-02-10 Genmab A/S Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
CA2513399A1 (en) 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
EP1689722A2 (en) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
AU2003297904A1 (en) 2003-12-12 2005-07-14 University Of Maryland, Baltimore Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain
EP1708712A1 (en) 2003-12-24 2006-10-11 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
US7622486B2 (en) 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
BRPI0606930A2 (pt) 2005-01-25 2009-12-01 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente
AU2006254834B2 (en) 2005-06-08 2012-09-20 Millennium Pharmaceuticals, Inc. Treatment of patients with cancer therapy
KR20080049767A (ko) 2005-08-26 2008-06-04 라보라뚜와르 세로노 에스. 에이. 피라진 유도체 및 ｐｉ３ｋ 억제제로서의 용도
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008070661A1 (en) 2006-12-04 2008-06-12 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
WO2008076883A2 (en) 2006-12-15 2008-06-26 Abraxis Bioscience, Inc. Triazine derivatives and their therapeutical applications
PT2152676E (pt) 2007-04-30 2013-06-25 Prometic Biosciences Inc Derivados de triazina, composições contendo tais derivados, e métodos de tratamento do cancro e de doenças autoimunes usando tais derivados
AU2008262291A1 (en) 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
BRPI0814628B1 (pt) 2007-07-20 2022-04-05 Nerviano Medical Sciences S.R.L. Derivados ativos de indazol substituídos como inibidores da quinase
WO2009027736A2 (en) * 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
CN101981010A (zh) 2007-10-10 2011-02-23 武田药品工业株式会社 酰胺化合物
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
JP5277685B2 (ja) 2008-03-26 2013-08-28 富士ゼロックス株式会社 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法
CN101575408B (zh) 2008-05-09 2013-10-30 Mca技术有限公司 用作阻燃剂和光稳定剂的聚三嗪基化合物
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
WO2010007756A1 (ja) 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
WO2010028179A1 (en) 2008-09-03 2010-03-11 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds as gata modulators
PL2546365T3 (pl) 2008-09-03 2017-07-31 The Johns Hopkins University Zmiany genetyczne w dehydrogenazie izocytrynianowej i innych genach w glejaku złośliwym
JP2010079130A (ja) 2008-09-29 2010-04-08 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
JP2010181540A (ja) 2009-02-04 2010-08-19 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
ES2453474T3 (es) 2009-02-06 2014-04-07 Nippon Shinyaku Co., Ltd. Derivados de aminopirazina y medicamento correspondiente
WO2010105243A1 (en) 2009-03-13 2010-09-16 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US8261872B2 (en) * 2009-06-08 2012-09-11 Clark Equipment Company Work machine having modular ignition switch keypad with latching output
AU2010259002B2 (en) * 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
CA2765050A1 (en) 2009-06-09 2010-12-16 California Capital Equity, Llc Ureidophenyl substituted triazine derivatives and their therapeutical applications
JP2012529518A (ja) 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ヘッジホッグシグナル伝達のピリジル−トリアジン阻害剤
WO2011005209A1 (en) 2009-07-10 2011-01-13 Milux Holding S.A. Knee joint device and method
JP5473851B2 (ja) 2009-09-30 2014-04-16 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
JP5967827B2 (ja) 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
EP2553116A4 (en) 2010-04-01 2013-10-23 Agios Pharmaceuticals Inc METHOD FOR IDENTIFYING A CANDIDATE COMPOUND
JP6081354B2 (ja) 2010-07-16 2017-02-15 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性組成物およびそれらの使用方法
CN103347866B (zh) 2010-11-29 2016-05-18 加林制药公司 作为治疗呼吸控制不适或疾病的呼吸兴奋剂的新化合物
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102659765B (zh) 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
CN107982266B (zh) 2012-01-06 2021-07-30 H.隆德贝克有限公司 氨基甲酸酯化合物及其制备和使用方法
SI2800743T1 (en) * 2012-01-06 2018-08-31 Agios Pharmaceuticals, Inc. Therapeutically active compounds and methods for their use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX350432B (es) 2012-01-19 2017-09-06 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de empleo.
US20150011751A1 (en) 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
BR112014016805B1 (pt) 2019-07-30
CN107417667B (zh) 2020-04-10
CN115536635A (zh) 2022-12-30
AU2017265096A1 (en) 2017-12-14
EP3406608B8 (en) 2022-01-19
JP6409081B2 (ja) 2018-10-17
CA2860623A1 (en) 2013-07-11
CL2014001793A1 (es) 2014-11-07
MY185206A (en) 2021-04-30
WO2013102431A1 (en) 2013-07-11
KR101893112B1 (ko) 2018-08-30
IL233503A0 (en) 2014-08-31
AU2013207289B2 (en) 2017-09-21
MX2014008350A (es) 2014-10-06
EP2800743B1 (en) 2018-04-04
CN108912066A (zh) 2018-11-30
JP6411895B2 (ja) 2018-10-24
ES2901430T3 (es) 2022-03-22
RS57401B1 (sr) 2018-09-28
HRP20180844T1 (hr) 2018-08-24
HK1203942A1 (en) 2015-11-06
PE20142098A1 (es) 2015-01-08
US20170044139A1 (en) 2017-02-16
US9512107B2 (en) 2016-12-06
CN104114543B (zh) 2019-03-15
DK2800743T3 (en) 2018-06-14
PH12014501561A1 (en) 2014-10-08
EP2800743A4 (en) 2015-08-26
NZ722582A (en) 2018-02-23
CN107417667A (zh) 2017-12-01
AR090411A1 (es) 2014-11-12
LT2800743T (lt) 2018-06-25
NZ627096A (en) 2017-02-24
CY1120506T1 (el) 2019-07-10
KR20140113712A (ko) 2014-09-24
AU2013207289A1 (en) 2014-07-31
AU2017265096B2 (en) 2019-08-08
PH12014501561B1 (en) 2014-10-08
UA117451C2 (uk) 2018-08-10
EA030187B1 (ru) 2018-07-31
TR201809228T4 (tr) 2018-07-23
PL2800743T3 (pl) 2018-09-28
EP3406608A1 (en) 2018-11-28
EA201491330A1 (ru) 2015-04-30
JP2017075193A (ja) 2017-04-20
US20230250078A1 (en) 2023-08-10
CN108912066B (zh) 2022-06-24
CR20140377A (es) 2014-11-13
ZA201405163B (en) 2018-05-30
NO2897546T3 (pt) 2018-01-13
CO7030962A2 (es) 2014-08-21
US20170298045A1 (en) 2017-10-19
SG11201403878QA (en) 2014-08-28
PT2800743T (pt) 2018-07-04
US9732062B2 (en) 2017-08-15
AU2017265096B9 (en) 2019-09-05
SI2800743T1 (en) 2018-08-31
JP2015503571A (ja) 2015-02-02
CN115521264A (zh) 2022-12-27
US9656999B2 (en) 2017-05-23
TWI653228B (zh) 2019-03-11
TW201329054A (zh) 2013-07-16
HUE038403T2 (hu) 2018-10-29
SG10201602862RA (en) 2016-05-30
US20220348554A1 (en) 2022-11-03
NI201400073A (es) 2014-12-22
EP2800743A1 (en) 2014-11-12
ES2675760T3 (es) 2018-07-12
MX358940B (es) 2018-09-10
EP3984997A1 (en) 2022-04-20
US10294215B2 (en) 2019-05-21
BR112014016805A2 (pt) 2017-06-13
IL233503B (en) 2018-07-31
ECSP14012726A (es) 2016-01-29
CN114933585A (zh) 2022-08-23
EP3406608B1 (en) 2021-09-15
US11505538B1 (en) 2022-11-22
US20200079755A1 (en) 2020-03-12
US20130190287A1 (en) 2013-07-25
AU2013207289A2 (en) 2014-07-31
CN104114543A (zh) 2014-10-22
US20160318903A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
BR112014016805A8 (pt) compostos terapeuticamente ativos e seus métodos de uso
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
BR112016002287A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
CR20140388A (es) Compuestos terapeuticamente activos y sus métodos de uso
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
BR112013001122A2 (pt) composições ativas terapêuticas e seu método de uso
BR112015011830A2 (pt) compostos e seus métodos de utilização
WO2015003355A3 (en) Therapeutically active compounds and their methods of use
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
UY36207A (es) Inhibidores de la syk
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
EA201391438A1 (ru) Производные сулиндака, применение и получение указанных производных
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
CR20160054A (es) Compuestos terapeuticamente activos y sus métodos de uso
UY34069A (es) Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: AGIOS PHARMACEUTICALS, INC. (US)

B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: CIENCIA RELACIONADA COM O ART.229-C DA LPI (ANUENCIA PREVIA) (DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. )

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/01/2013, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/01/2013, OBSERVADAS AS CONDICOES LEGAIS